Loading
A phase 3 trial of Daromun in melanoma, run by Philogen S.p.A., now recruiting.
Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients is a phase 3 interventional study registered as NCT03567889 by Philogen S.p.A., with 186 participants planned, started 2018-09-20 and due to reach its primary completion in 2027-12. Interventions recorded: Daromun, Surgery and Adjuvant therapy.
Shares Philogen S.p.A., Stage III melanoma (after surgery), Melanoma and the tag pipeline.
Shares Philogen S.p.A. and the tag pipeline.
Shares Philogen S.p.A. and the tag pipeline.
Shares Philogen S.p.A. and the tag pipeline.
Shares Philogen S.p.A. and the tag pipeline.
Shares Stage III melanoma (after surgery), Melanoma and the tag pipeline.
Shares Melanoma and the tag pipeline.
Shares Melanoma and the tag pipeline.